BTIG initiated coverage on Sigilon Therapeutics with a new price target
$SGTX
Medicinal Chemicals and Botanical Products
Health Care
BTIG initiated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $14.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2021 | $12.00 → $7.00 | Buy | Canaccord Genuity |
| 12/1/2021 | $16.00 → $7.00 | Overweight | Barclays |
| 11/30/2021 | $9.00 → $4.50 | Equal-Weight | Morgan Stanley |
| 11/30/2021 | $15.00 → $4.00 | Buy → Hold | Jefferies |
| 10/29/2021 | $14.00 | Buy | BTIG |
| 8/2/2021 | $15.00 | Buy | Jefferies |
| 7/19/2021 | $62.00 → $43.00 | Buy | Canaccord Genuity |
| 7/16/2021 | $45.00 → $9.00 | Equal-Weight | Morgan Stanley |
Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Royal Caribbean Cruises The Trade: Royal Caribbean Cruises Ltd. (NYSE:RCL) Director Maritza Gomez Montiel acquired a to
Canaccord Genuity analyst Whitney Ijem maintains Sigilon Therapeutics (NASDAQ:SGTX) with a Buy and raises the price target from $6 to $30.
Morgan Stanley analyst Matthew Harrison maintains Sigilon Therapeutics (NASDAQ:SGTX) with a Equal-Weight and raises the price target from $7 to $21.
INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ:SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. "Make life better – that's the phrase that guides everything we do at Lilly," said Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and cardiometabolic research at Lilly. "We are excited to welcome our new colleagues from Sigilon to Lilly; together, we will strive to provide solutions for people living with type 1 diabetes that absolves them of cons
NEW YORK, July 15, 2023 (GLOBE NEWSWIRE) -- Kaleyra, Inc. (NYSE:KLR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of KLR to Tata Communications Limited for $7.25 per share in cash. If you are a KLR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Conformis Inc. (NASDAQ:CFMS) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CFMS to Restor3d, Inc. for $2.27 per share in cash.
INDIANAPOLIS and CAMBRIDGE, Mass., June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Sigilon Therapeutics, Inc. (NASDAQ:SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases. Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The goal of these therapies is to free patients from constant disease management by sensing blood glucose levels, restoring insulin production and releasing it over the long term. "Despite significant advanceme
SC 13G/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC 13D/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC 13D - Sigilon Therapeutics, Inc. (0001821323) (Subject)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities. Werner most recently served as Wo
Announced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization Strengthened leadership team with appointment of new Chief Technical Operations Officer and other key leadership changes Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2021 as well as
CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2021 as well as certain other business highlights. "We are continuing to execute on our business plan in 2021, as we advance the clinical development of our lead product candidate for hemophilia A, while at the same time working to strengthen our team, expanding our pipeline and further validating the potential of our Shielded Living Therapeutics™, or SLTx, platform," commented Rogerio Vivald
Canaccord Genuity reiterated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $7.00 from $12.00 previously
Barclays reiterated coverage of Sigilon Therapeutics with a rating of Overweight and set a new price target of $7.00 from $16.00 previously
Morgan Stanley reiterated coverage of Sigilon Therapeutics with a rating of Equal-Weight and set a new price target of $4.50 from $9.00 previously
15-12G - Sigilon Therapeutics, Inc. (0001821323) (Filer)
EFFECT - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)